Meeting
2019 Genitourinary Cancers Symposium
Relationships between anticancer effects and serum gemcitabine levels, human antigen-R expression, and their combination in advanced urothelial cancer treated with gemcitabine and platinum agents.
Authors
Yuji Sagara
Nagasaki University Hospital, Nagasaki, Japan
Yuji Sagara , Yasuyoshi Miyata , Tsutomu Yuno , Kyohei Araki , Yuichiro Nakamura , Tomohiro Matsuo , Kojiro Ohba , Hideki Sakai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 445)
DOI
10.1200/JCO.2019.37.7_suppl.445
Abstract #
445
Poster Bd #
J16
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Sequential chemotherapy with gemcitabine+carboplatin followed by gemcitabine+carboplatin+docetaxel for advanced upper-tract urothelial cancer.
First Author: Takahiro Yoneyama
Poster
2018 Genitourinary Cancers Symposium
Significance of serum buttyrylcholinesterase level before chemotherapy as an independent predictor of overall survival in patients with metastatic upper-tract urothelial cancer.
First Author: Takahiro Yoneyama
Poster
2017 ASCO Annual Meeting
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
First Author: Thomas Powles
Poster
2016 Genitourinary Cancers Symposium
TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.
First Author: Robert J. Jones